Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVJF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
tevjf · stock forecast · 39 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 39 Wall Street analysts in the past 3 months
Hold
39 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $30.34
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $30.44 | ↑ 0.33% |
1-day model range: $30.39–$30.49. Peak: $30.49 (+0.33%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TEVJF · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-09-19 | UBS | Maintains | Neutral→Neutral |
| 2023-09-07 | B of A Securities | Maintains | Buy→Buy |
| 2023-07-05 | UBS | Upgrade ↑ | Sell→Neutral |
| 2023-05-25 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2023-05-17 | Evercore ISI Group | Upgrade ↑ | In Line→Outperform |
| 2023-05-10 | B of A Securities | Maintains | Buy→Buy |
| 2023-02-08 | Barclays | Maintains | Overweight→Overweight |
| 2023-01-18 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2022-11-22 | Piper Sandler | Maintains | Underweight→Underweight |
| 2022-11-13 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
Wall Street analysts have recently issued updated ratings on Teva Pharmaceutical Industries Limited (TEVJF) stock. Of the recent 199 rating actions, 47 were upgrades and 46 were downgrades. 39 analysts currently cover TEVJF.
Analyst Recommendation Trends
TEVJF analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$16.8B
↓ 7.6% YoY
Revenue Next Year
$17.5B
↑ 4.1% YoY
EPS This Year
$2.29
EPS Next Year
$3.14
↑ 37.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast TEVJF EPS of $2.29 for the current fiscal year, based on estimates from 1 analysts. The TEVJF revenue forecast is $16.8B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TEVJF stock forecast is supported by two independent data sources: analyst consensus ratings from 39 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TEVJF price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The TEVJF short-term stock prediction for tomorrow is $30.44 (+0.33%).
Teva Pharmaceutical Industries Limited trades on OTC under the ticker TEVJF. The TEVJF stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 31% of covering analysts.
Frequently asked questions
TEVJF forecast · 8 questionsAccording to 39 Wall Street analysts, the average 12-month TEVJF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $30.34.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.